Bora Pharmaceuticals Co., Ltd. — Cyborg Score 7/10

Strategic Profile

Bora is a premier international CDMO specializing in formulation development, clinical and commercial manufacturing, and packaging of complex oral solid dose, liquid, semi-solid, biologics, and sterile injectable pharmaceutical products, delivering to more than 100 markets around the world. The company operates across Taiwan, the United States, and Canada, with more than 95% of revenue generated outside Taiwan.

Cyborg Score Rationale

Bora demonstrates strong operational execution with recent capacity expansions, growing CDMO capabilities, and solid ESG credentials. Recent sustainability recognitions and U.S. market expansion via OTCQX listing enhance visibility. However, valuation concerns and market positioning challenges require monitoring.

Top Insights

• Recently expanded CDMO footprint with new Zhongli facility for small molecule dose forms (July 2025)
• Received multiple ESG recognitions including MSCI 'A' rating and inclusion in FTSE4Good Index (Dec 2025)
• Expanded U.S. investor access through OTCQX Level 1 ADR program (January 2026)
• More than 95% of revenue derived from international markets outside Taiwan, with established facilities in North America and Asia

Named Competitors

• Contract Development and Manufacturing — Global CDMO competitors
• Specialty Pharmaceutical Distribution — Taiwan-based pharma competitors

Recent Developments

• (January 2026) Began trading on OTCQX under symbol BORAY, expanding U.S. investor access
• (December 2025) Achieved MSCI ESG Rating of 'A' and FTSE Russell ESG Score of 3.5/5
• (September 2025) Added liquid-filled hard capsule (LFC) production capabilities at Zhunan facility
• (July 2025) Unveiled new multi-purpose small molecule dose form facility in Zhongli, Taiwan

Open the full interactive Bora Pharmaceuticals Co., Ltd. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.